Compare Hasbro, Inc. (HAS) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hasbro, Inc. vs Sana Biotechnology Inc — how do they compare? Hasbro, Inc. trades at $95.66 (market cap $13.69B), while Sana Biotechnology Inc trades at $3.76 (market cap $1.13B). The key difference: Hasbro, Inc. is far larger — about 12.1× Sana Biotechnology Inc's market cap, and Hasbro, Inc. pays a 2.89% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.
| HAS | SANA | |
|---|---|---|
Market Cap | $13.69B | $1.13B |
Sector | Consumer Cyclical | Health |
52-Week High | $105.88 | $5.92 |
52-Week Low | $70.95 | $2.68 |
Enterprise Value | $15.88B | $1.05B |
Dividend Yield | 2.89% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hasbro (HAS) trades at $96.19, up 1.8% today, with a bullish technical outlook from moving averages and a consensus analyst price target of $104.90. Recent earnings beats in Q4 2025, Q1 2026, and Q2 2026 highlight strong operational performance, though 2025 net income was negative due to a one-time tax charge. Revenue growth is projected to rebound to $5.0B in 2026, with a net income margin of 16%, supported by strength in the Wizards of the Coast segment.
The stock offers upside potential from earnings momentum and dividend yield, but risks include high debt levels, margin pressures, and competitive threats. Institutional buying and positive media coverage on franchises like Magic: The Gathering provide tailwinds, yet volatility from tariffs and execution risks warrants caution for investors seeking growth in the consumer discretionary sector.
SANA Biotechnology trades at $3.77, up 4.43% today, with a bullish technical signal from moving averages and ADX indicators. The company reported a net loss of $244.17 million for 2025, with negative cash flow from operations, but analyst consensus is strongly positive with 82% buy ratings. Recent news highlights clinical data presentations and a $9.50 average price target from brokerages as of July 30, 2026.
The outlook hinges on clinical progress driving future profitability, but high cash burn and negative ROE pose significant risks. Upside potential exists if pipeline milestones are met, supported by institutional optimism, though investors face volatility from earnings misses and funding needs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Hasbro, Inc.
Hasbro is a branded play company providing children and families around the world with entertainment offerings based on a world-class brand portfolio. From toys and games to television programming, motion pictures, and a licensing program, Hasbro reaches customers by leveraging its well-known brands such as Transformers, Nerf, and Magic: The Gathering. Ownership stakes in Discovery Family, which offers programming around Hasbro brands, and owned production capabilities from Entertainment One help bolster Hasbro's multichannel presence. The firm acquired Entertainment One in 2019, bolting on popular properties like Peppa Pig and PJ Masks, and has plans to tie up with Dungeons & Dragons Beyond in 2022, offering the firm access 10 million digital tabletop players.
Read more on HAS →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
